WallStreetZenWallStreetZen

NASDAQ: JAGX
Jaguar Health Inc Stock

$4.09+0.04 (+0.99%)
Updated Jul 11, 2024
JAGX Price
$4.09
Fair Value Price
N/A
Market Cap
$20.14M
52 Week Low
$3.07
52 Week High
$41.76
P/E
-0.1x
P/B
1.68x
P/S
1.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.14M
Earnings
-$38.32M
Gross Margin
79.1%
Operating Margin
-330.49%
Profit Margin
-377.9%
Debt to Equity
3.42
Operating Cash Flow
-$30M
Beta
0.76
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

JAGX Overview

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how JAGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

JAGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JAGX is good value based on its book value relative to its share price (1.68x), compared to the US Biotechnology industry average (6.37x)
P/B vs Industry Valuation
JAGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more JAGX due diligence checks available for Premium users.

Be the first to know about important JAGX news, forecast changes, insider trades & much more!

JAGX News

Valuation

JAGX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.1x
Industry
-14.46x
Market
31.84x

JAGX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.68x
Industry
6.37x
JAGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

JAGX's financial health

Profit margin

Revenue
$2.4M
Net Income
-$9.2M
Profit Margin
-392.4%
JAGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
JAGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$55.4M
Liabilities
$41.1M
Debt to equity
3.42
JAGX's short-term assets ($33.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JAGX's short-term assets ($33.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JAGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JAGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.0M
Investing
$0.0
Financing
$12.3M
JAGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

JAGX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
JAGX$20.14M+0.99%-0.10x1.68x
CARA$20.01M+27.97%-0.16x0.67x
VIRX$19.64M+3.09%-0.41x1.77x
VINC$19.49M+1.54%-0.37x-31.34x
APM$20.93M+7.45%-6.52x0.84x

Jaguar Health Stock FAQ

What is Jaguar Health's quote symbol?

(NASDAQ: JAGX) Jaguar Health trades on the NASDAQ under the ticker symbol JAGX. Jaguar Health stock quotes can also be displayed as NASDAQ: JAGX.

If you're new to stock investing, here's how to buy Jaguar Health stock.

What is the 52 week high and low for Jaguar Health (NASDAQ: JAGX)?

(NASDAQ: JAGX) Jaguar Health's 52-week high was $41.76, and its 52-week low was $3.07. It is currently -90.21% from its 52-week high and 33.14% from its 52-week low.

How much is Jaguar Health stock worth today?

(NASDAQ: JAGX) Jaguar Health currently has 4,924,572 outstanding shares. With Jaguar Health stock trading at $4.09 per share, the total value of Jaguar Health stock (market capitalization) is $20.14M.

Jaguar Health stock was originally listed at a price of $96,109,815.79 in May 13, 2015. If you had invested in Jaguar Health stock at $96,109,815.79, your return over the last 9 years would have been -100%, for an annualized return of -84.83% (not including any dividends or dividend reinvestments).

How much is Jaguar Health's stock price per share?

(NASDAQ: JAGX) Jaguar Health stock price per share is $4.09 today (as of Jul 11, 2024).

What is Jaguar Health's Market Cap?

(NASDAQ: JAGX) Jaguar Health's market cap is $20.14M, as of Jul 12, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Jaguar Health's market cap is calculated by multiplying JAGX's current stock price of $4.09 by JAGX's total outstanding shares of 4,924,572.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.